Biological Product (except Diagnostic) Manufacturing — U.S. Industry Primer

NAICS 2022 code 325414. NAICS = North American Industry Classification System, the standard code set the U.S. government uses to group businesses.

1. Overview

This is the industry that makes biologics — medicines produced from living cells or living-organism materials rather than mixed from chemicals. It covers vaccines, blood- and plasma-derived therapies, therapeutic proteins, monoclonal antibodies (lab-grown antibodies used against cancer and autoimmune disease), gene and cell therapies, allergenic extracts, and antitoxins [1]. In plain terms: if a drug is grown rather than synthesized, its factory usually sits in this code.

Why an investor should care: biologics are now roughly 37–38% of all U.S. prescription-drug spending and the fastest-growing slice of medicine, because most new blockbuster therapies are large molecules, not pills [5][6]. As of March 2026, FDA noted that biologics accounted for only 5% of U.S. prescriptions but 51% of drug spending — a concentration that makes the category an attractive target for payers, policymakers, and follow-on manufacturers [22]. Biologics are also unusually hard to make — living-cell production, sterile handling, and multi-year regulatory approval create deep moats and fat margins for whoever owns the approved factory and license.

There are two distinct ways in, and they behave differently. Public-market investors can buy pure-play specialists, plasma majors, diversified pharma with big biologic franchises, or the "picks-and-shovels" contract manufacturers and tools suppliers. Private investors show up as venture and growth backers of platform biotechs, as owners of privately held plasma collectors and contract manufacturers, and — increasingly — as infrastructure capital financing the wave of new U.S. plants. The end-customer for much of the industry is not a consumer at all but the government (stockpiles, biodefense, Medicare reimbursement).

2. What it is, and how it's structured

In scope (325414): vaccines and toxoids; blood fractions and plasma-derived products (immune globulin, albumin, clotting factors); therapeutic serums and antitoxins; monoclonal antibodies and other therapeutic proteins; gene- and cell-therapy products; culture media of plant or animal origin [1]. Veterinary vaccines, bacterins, antisera, and related products are also in scope, with regulatory oversight by USDA's Center for Veterinary Biologics rather than FDA [23].

What it explicitly excludes — and the adjacent codes:

• 325412 — Pharmaceutical Preparation Manufacturing: conventional (small-molecule, chemically synthesized) drugs, and the final "fill-finish" and formulation of many medicines. This is the neighbor that causes most of the measurement confusion below.
• 325413 — In-Vitro Diagnostic Substance Manufacturing: biological products used to test rather than treat — the "except Diagnostic" carve-out in the name.
• 325411 — Medicinal and Botanical Manufacturing: bulk active ingredients and botanical extracts.

Why manufacturing is part of the product. Biologics are heterogeneous and difficult to characterize completely. NIST describes them as chemically and structurally complex and notes that predictive control of quality at scale remains difficult [24]. Seemingly modest changes to a cell line, raw material, scale, site, or purification step may require comparability work and regulatory approval. A Biologics License Application must demonstrate not only safety and efficacy but also that the product can be manufactured consistently to quality standards; FDA commonly performs pre-approval and surveillance inspections for current good manufacturing practice compliance [25].

Ownership mix. The domestic base is a mix of a few very large, mostly foreign-headquartered specialists (plasma and vaccines), several U.S. pure-play biologics companies, the biologics plants of diversified pharma, a fast-growing contract-manufacturing tier (CDMOs), and government-tied biodefense suppliers. It is capital-heavy and licence-gated: you cannot enter quickly, because a single biologics plant can cost $1–2 billion and take years to build and win approval [18].

3. How big it is (federal ground truth, and its blind spot)

U.S. Census Bureau figures for establishments physically classified in 325414:

Average payroll works out to about $125,000 per employee — very high for "manufacturing," reflecting scientists, engineers, and quality staff rather than line labor [2].

The blind spot — read this before using the $47.3 billion. That receipts figure measures the ex-factory shipments of U.S. establishments primarily classified in 325414. It is not the size of the U.S. biologics market, which private estimates put well north of $200 billion, inside a global biologics market around $626 billion in 2025 with North America holding the largest share [5]. Three reasons for the gap: (1) much of the biologic sold in the U.S. is either imported or finished at plants classified under 325412 (pharmaceutical preparation), so its value lands in a different code; (2) receipts are factory revenue, not the marked-up prescription spend that includes distribution and pharmacy margins; and (3) a diversified drugmaker's biologics plant may be counted under whatever the parent's primary code is. So treat the federal numbers as an accurate read on the domestic factory footprint — real, but a partial slice of the money biologics actually move.

Don't confuse manufacturing with biotech R&D. Pure research establishments belong in biotechnology R&D — Census counted 5,670 employer establishments in NAICS 541714 in 2023, versus 441 manufacturing establishments in 325414 [26]. Many clinical-stage biotechnology companies own no factory at all.

4. The investable universe

There is no single U.S.-listed "pure biologics manufacturing" stock that captures the whole industry; exposure is assembled from several buckets. (Scale figures are recent reported revenue and are approximate.)

Major private / other owners (no common stock, or foreign-only): Octapharma and Kedrion (privately held plasma fractionators); Boehringer Ingelheim (private German firm, large biologics contract manufacturer); Catalent (leading contract manufacturer, taken private by Novo Holdings in 2024); and, critically, the U.S. government — via the Biomedical Advanced Research and Development Authority (BARDA) and the Strategic National Stockpile — as the anchor customer for vaccines and biodefense products [9][18].

Contract manufacturers (CDMOs). Lonza reported CHF6.5 billion of 2025 sales with a 31.6% "CORE EBITDA" margin and CHF1.3 billion of capital expenditure, with higher biologics utilization helping margins [31]. Other major CDMOs include Samsung Biologics and Thermo Fisher/Patheon.

Picks-and-shovels suppliers. Bioprocess equipment and consumables suppliers — Thermo Fisher, Danaher, Sartorius, Repligen — sell media, filtration, chromatography, single-use systems, and analytical equipment into every biologics plant, giving exposure with less dependence on a single therapy [32].

5. How the money works

Owners in this industry make money in ways specific to grown-not-mixed medicine:

• Exclusivity is the real revenue engine. A newly licensed biologic gets 12 years of data exclusivity under U.S. law, on top of patents, before a copy ("biosimilar") can be approved [16]. Revenue is best understood as a function of the remaining exclusivity runway — pricing power is near-monopoly during it and erodes fast after. Keytruda's ~$32 billion (2025) versus Humira's steady biosimilar-driven decline is the same story at two ends of the clock [21].
• Gross margin and capacity utilization. These are high-fixed-cost plants; profitability turns on keeping bioreactors and fill-finish lines full and on yield (grams of product per liter). Even a focused specialist like ADMA runs a ~57% gross margin, and big-pharma branded biologics run far higher [8]. But "biologics are high margin" is incomplete: Moderna's 2025 cost of sales was $868 million (48% of net product sales), including $291 million of inventory write-downs and $93 million of unutilized-capacity and wind-down costs — capacity, inventory, and forecast errors can destroy the realized margin [33].
• The plasma model is a supply-chain business. Plasma companies are vertically integrated: they run paid donor collection centers (typical U.S. donor pay is ~$40–80 per donation, with new-donor bonuses up to ~$700–750 a month), then fractionate one liter of plasma into multiple products — immune globulin, albumin, clotting factors [13]. The economics hinge on collection volume and on extracting the most value per liter. Grifols explicitly identifies plasma cost per liter, donation-center productivity, fractionation yield, and vertical sourcing as margin drivers [34]. Immune globulin (IG) is the profit driver, growing double-digits [12].
• Government contracts are lumpy. Biodefense and stockpile revenue arrives as purchase options exercised on the government's timetable, so quarterly results swing on procurement timing rather than end-demand — Emergent's anthrax vaccine sales are the textbook case [9].
• The contract-manufacturer model (CDMO = Contract Development and Manufacturing Organization) sells capacity: take-or-pay reservations, multi-year backlog, and utilization of very expensive suites [18].

Cost structure across the board: skilled labor, raw materials (plasma, cell-culture media), obsessive quality control, cold-chain logistics, and heavy capital spending.

6. What drives demand

• Aging and chronic disease — cancer, autoimmune conditions, and rare diseases are disproportionately treated with biologics.
• Immune-globulin growth — rising diagnosis of immunodeficiency and neurological uses keeps IG demand growing faster than plasma supply, the sector's tightest bottleneck [12].
• Vaccines — routine immunization, seasonal flu, and pandemic preparedness. The global vaccine market was roughly $89 billion in 2025 [7]. COVID demand has fallen sharply, which is why Moderna's revenue dropped ~39% in 2025 [19]. Demand can shift through dosing schedules as well as patient counts — Merck's 2025 filing notes that worldwide Gardasil/Gardasil 9 sales declined after weaker Chinese demand and changes in immunization cohorts, even as U.S. pricing and government purchasing helped domestic sales [35].
• Biosimilar entry — expands patient access and volume even as it erodes originator pricing. As of March 2026, FDA had approved 82 biosimilars [22][16][21].
• Supply-chain security and reshoring — policy pressure to move biologics production out of China (the proposed BIOSECURE Act) plus tax and biosecurity incentives are pulling capacity to the U.S. [18].
• Veterinary demand — tied to pet-care spending, livestock economics, animal-protein consumption, and disease incidence. Zoetis identifies pet ownership, disposable income, longer companion-animal lives, livestock epidemiology, and vaccine adoption as key demand variables [30].

7. Regulation

• FDA / CBER. Biologics are regulated by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) under 21 CFR Parts 600–680. FDA's regulatory conception of biologics includes vaccines, blood and plasma products, allergenics, recombinant proteins, live biotherapeutics, and cell, gene, and tissue therapies [36]. Approval comes through a Biologics License Application (BLA) under Section 351(a) of the Public Health Service Act; biosimilars use the abbreviated 351(k) pathway [15].
• Manufacturing rules. Current Good Manufacturing Practice (cGMP), routine facility inspections, and batch-by-batch release. A failed inspection can halt a product line. FDA states that manufacturing-quality problems are the most common cause of drug shortages and notes that long lead times and limited alternative capacity make rapid recovery difficult [37].
• BPCIA (Biologics Price Competition and Innovation Act, 2010). Created the biosimilar pathway and the 12-year reference-product exclusivity, plus the patent-litigation "dance" between originator and biosimilar [16].
• IRA (Inflation Reduction Act) Medicare price negotiation. Medicare can now negotiate prices on high-spend drugs; a biologic becomes eligible after it has been licensed 11 years, with negotiated prices phasing in from 2026. Notably, biologics get about 13 years of market pricing before negotiation bites versus 9 years for small-molecule pills — a structural advantage that steers investment toward large molecules [17].
• Plasma and reimbursement. The FDA also regulates source-plasma collection and donor safety. Infused biologics are largely paid through Medicare Part B "buy-and-bill," so CMS (Centers for Medicare & Medicaid Services) reimbursement policy directly shapes demand.
• Veterinary biologics. Veterinary vaccines, bacterins, antisera, and related products are overseen by USDA's Center for Veterinary Biologics rather than FDA [23].

8. Competitive dynamics and consolidation

The federal concentration statistics look deceptively gentle: the top 4 firms hold 30.7% of receipts, the top 20 hold 73.9%, and the Herfindahl-Hirschman Index (HHI, a standard concentration gauge) is 404.8 — well inside "unconcentrated" territory [3]. But that measures all biologic types lumped together across the domestic factory base. Inside any single therapeutic market the picture is the opposite: an on-patent originator biologic is effectively a monopoly, and the plasma business is a tight oligopoly, with CSL, Grifols, Takeda, and Octapharma controlling an estimated 70–80% of U.S. fractionation and collection [12].

Consolidation is active on two fronts. Big pharma keeps buying biologic innovators to refill pipelines. And the contract-manufacturing tier is being reshaped by capital: Novo Holdings took Catalent private, and Lonza bought Genentech's Vacaville, California plant for $1.2 billion to add U.S. capacity [18]. Roughly $24.9 billion in new CDMO capacity was announced in 2025, with about 74% flowing to the United States [18].

9. Risks

• Patent cliffs and biosimilar erosion. When exclusivity ends, revenue can fall by billions fast (Humira) [21].
• Price-control pressure. IRA negotiation and broader drug-pricing politics cap the pricing power that underwrites the whole model [17].
• Manufacturing failure. Contamination, batch loss, or an FDA inspection finding can stop production. Emergent's Baltimore COVID-vaccine plant failure in 2021 is a cautionary example of how quickly a quality lapse destroys a franchise. FDA says manufacturing-quality problems are the most common cause of drug shortages, and that long lead times and limited alternative capacity make rapid recovery difficult [37].
• Supply-chain fragility. An alternative resin, filter, cell-culture component, plasma source, or fill-finish line may need qualification and regulatory approval. Single-source consumables, specialized equipment, and cold-chain providers matter more than their accounting cost suggests.
• Plasma supply shocks. Collections collapsed during COVID lockdowns; the sector's raw material depends on paid human donors.
• Demand and capacity whiplash. The COVID mRNA boom-and-bust shows how fast government/pandemic demand can reverse and strand capacity [19][33].
• Government and political dependence. Biodefense and stockpile revenue rides on federal budgets and procurement timing [9].
• Concentration and policy scrutiny of paid plasma. The U.S. supplies roughly 70% of the world's source plasma, and blood products are around 1.8% of total U.S. goods exports — worth on the order of $37 billion and ranking as a top-ten export — a dependence that invites ethical and regulatory attention abroad [14].
• Trade and reshoring policy risk cuts both ways: incentives today, tariffs or mandates tomorrow.
• Labor constraints. A modern plant requires bioprocess engineers, microbiologists, automation specialists, aseptic operators, quality-control analysts, validation personnel, and regulatory-quality leadership. The relevant risk is not simply wage inflation but whether a site can hire and retain enough experienced people to start up, investigate deviations, and release product without compromising compliance.

10. How to invest, and the outlook

Public-market routes. Four buckets, roughly from focused to diversified:

1. Near pure-plays — a U.S. immune-globulin specialist (ADMA), vaccine developers (Moderna, Novavax), and a biodefense supplier (Emergent).
2. Plasma majors — CSL (Australia-listed), Grifols (Nasdaq ADR), Takeda (NYSE ADR). Note: American Depositary Receipt (ADR) = a U.S.-traded certificate representing foreign shares.
3. Diversified pharma whose value includes a major biologic franchise — Merck (Keytruda), Pfizer (Comirnaty), Sanofi (vaccines), and other large biologic makers.
4. Picks-and-shovels — the contract manufacturers (Lonza, Samsung Biologics, Fujifilm) and the bioprocessing suppliers (Thermo Fisher, Danaher, Sartorius, Repligen) that sell into every biologics plant [32]. Broad biotech and pharma ETFs (exchange-traded funds) give diversified but non-targeted exposure; note that funds like IBB target biotechnology equities engaged mainly in therapeutic R&D and do not track NAICS 325414 or isolate manufacturing economics [38].

Private-market routes. Venture and growth equity in platform biotechs pre-approval; direct ownership of privately held plasma fractionators (Octapharma, Kedrion) and contract manufacturers (Catalent under Novo Holdings, Boehringer Ingelheim); infrastructure and real-asset capital financing the U.S. plant build-out; and government-contractor plays tied to BARDA and the national stockpile.

Near-term drivers to watch (forward-looking). The strongest tailwinds are the reshoring capacity wave and BIOSECURE-style supply-security policy pulling manufacturing onshore [18]; durable double-digit immune-globulin demand against tight plasma supply [12]; and a widening biosimilar wave that expands volume while compressing originator pricing [16][21]. The strongest headwinds are IRA price negotiation and the general politics of drug pricing [17], plus the sector's chronic exposure to manufacturing mishaps and lumpy government demand. The reasonable expectation is steady structural growth in biologics as a share of medicine, with the domestic factory footprint expanding faster than the headline federal figures — because a large part of that growth is precisely the reshoring the 2022–2023 statistics have not yet captured.

---

Sources

1. U.S. Census Bureau / NAICS Association. "NAICS Code 325414 — Biological Product (except Diagnostic) Manufacturing" (2022 definition). https://www.naics.com/naics-code-description/?code=325414
2. U.S. Census Bureau. "County Business Patterns, 2023 — NAICS 325414" (establishments, employment, annual payroll). https://www.census.gov/programs-surveys/cbp.html
3. U.S. Census Bureau. "2022 Economic Census — Concentration Ratios / Statistics, NAICS 325414" (firms, receipts, CR4/CR8/CR20/CR50, HHI). https://www.census.gov/programs-surveys/economic-census.html
4. U.S. Small Business Administration. "Table of Small Business Size Standards, NAICS 325414" (2023). https://www.sba.gov/document/support-table-size-standards
5. Grand View Research. "Biologics Market Size, Share & Growth Report" (2025). https://www.grandviewresearch.com/industry-analysis/biologics-market
6. Grand View Research / JAMA. "Biologics as a share of U.S. drug spending (~37–38%)" (2025). https://www.grandviewresearch.com/industry-analysis/biologics-market
7. Fortune Business Insights. "Top Vaccine Companies / Vaccine Market Size (~$89B, 2025)" (2025). https://www.fortunebusinessinsights.com/blog/top-vaccine-companies-11071
8. ADMA Biologics, Inc. "Record Fourth Quarter and Full Year 2025 Financial Results" (2026). https://www.biospace.com/press-releases/adma-biologics-reports-record-fourth-quarter-and-full-year-2025-financial-results
9. Emergent BioSolutions Inc. "Fourth Quarter and Full Year 2025 Financial Results" (2026). https://www.globenewswire.com/news-release/2026/02/26/3246081/33240/en/Emergent-BioSolutions-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html
10. CSL Limited. "CSL Annual Report 2025" (FY2025 revenue and net profit). https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf
11. Wikipedia / Nasdaq. "Grifols" (2024 revenue, plasma centers, GRFS ADR listing). https://en.wikipedia.org/wiki/Grifols
12. PR Newswire / MarketsandMarkets. "Plasma Fractionation Market — CSL, Grifols, Takeda, Octapharma" (2024–2025). https://www.marketsandmarkets.com/ResearchInsight/plasma-fractionation-market.asp
13. GoodRx / LogicalDollar. "How Much Can You Make Donating Plasma; U.S. plasma center count" (2026). https://www.goodrx.com/health-topic/finance/how-much-donating-plasma-pays
14. CNBC / Econlib / Newsweek. "Why blood makes up over 2.5% of U.S. exports; U.S. ~70% of world source plasma" (2022–2025). https://www.cnbc.com/2022/06/30/why-blood-makes-up-over-2point5percent-of-all-us-exports.html
15. Fish & Richardson / FDA CBER. "How Biosimilars Are Approved; BLA and 21 CFR 600–680" (2024). https://www.fr.com/insights/ip-law-essentials/how-biosimilars-approved-litigated-patent-dance-timeline/
16. Bloomberg Law / GaBI Online. "The Biologics Price Competition and Innovation Act — 12-year exclusivity" (2024). https://gabionline.net/biosimilars/general/Biosimilars-and-US-exclusivity
17. Congressional Research Service / KFF. "Medicare Drug Price Negotiation under the IRA (biologics eligible after 11 years; 13 vs 9 years)" (2025). https://www.congress.gov/crs-product/R47872
18. PharmaSource. "The Great Reshoring: How $24.86 Billion Reshaped CDMO Manufacturing in 2025" (Lonza Vacaville, Fujifilm N.C., U.S. share). https://pharmasource.global/content/news/cdmo-news/the-great-reshoring-how-24-86-billion-reshaped-cdmo-manufacturing-in-2025/
19. Moderna, Inc. / Statista. "Moderna FY2025 revenue $1.94B (down ~39%)" (2026). https://www.statista.com/statistics/1107794/revenue-and-net-income-moderna-inc/
20. Novavax, Inc. "Third Quarter 2025 Financial Results / FY2025 adjusted revenue guidance" (2025). https://www.sec.gov/Archives/edgar/data/1000694/000100069425000048/nvax3q25earningspressrelea.htm
21. Statista / BioSpace / DrugPatentWatch. "Keytruda ~$32B (2025); Humira biosimilar erosion" (2025). https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/
22. U.S. Food and Drug Administration. "FDA Takes Further Steps to Streamline Biosimilar Development — 82 biosimilars approved; biologics 5% of prescriptions, 51% of spending" (March 2026). https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable
23. USDA APHIS. "Veterinary Biologics Common Questions" (veterinary vaccine oversight). https://www.aphis.usda.gov/veterinary-biologics/common-questions
24. NIST. "Manufacturing Standards for Biopharmaceuticals" (product complexity and quality control). https://www.nist.gov/blogs/taking-measure/manufacturing-standards-biopharmaceuticals-qa-nists-sheng-lin-gibson-and-vijay
25. U.S. Food and Drug Administration. "Biologics License Applications (BLA) Process (CBER)" (pre-approval inspections). https://www.fda.gov/vaccines-blood-biologics/development-approval-process-CBER/biologics-license-applications-bla-process-CBER
26. U.S. Census Bureau. "NAICS 541714 — Research and Development in Biotechnology (except Nanobiotechnology)" (5,670 establishments, 2023). https://data.census.gov/profile/541714_-_Research_and_Development_in_Biotechnology_%28except_Nanobiotechnology%29?codeset=naics~541714
27. ADMA Biologics, Inc. "2025 Annual Report (Form ARS)" (280+ plasma collection centers, gross margin). https://www.sec.gov/Archives/edgar/data/1368514/000114036126014803/ny20064057x3_ars.pdf
28. Emergent BioSolutions Inc. "2025 Form 10-K" ($742.9M revenue, 45% gross margin). https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm
29. Sanofi. "2025 Form 20-F" (€7.936B vaccine sales). https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm
30. Zoetis Inc. "2025 Form 10-K" (veterinary biologics, demand drivers). https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/zts-20251231.htm
31. Lonza Group AG. "2025 Financial Report" (CHF6.5B sales, 31.6% CORE EBITDA margin, CHF1.3B capex). https://www.lonza.com/annualreport/2025/pages/financials
32. Thermo Fisher Scientific Inc. "2025 Form 10-K" (bioproduction portfolio). https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm
33. Moderna, Inc. "2025 Form 10-K" (cost of sales detail: $868M / 48%, $291M write-downs, $93M unutilized capacity). https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm
34. Grifols S.A. "2025 Form 20-F" (plasma cost and yield drivers). https://www.sec.gov/Archives/edgar/data/1438569/000110465926044901/grfs-20251231x20f.htm
35. Merck & Co., Inc. "2025 Form 10-K" (Gardasil demand shifts). https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
36. U.S. Food and Drug Administration. "Science & Research (Biologics)" (regulatory scope of biologics). https://www.fda.gov/vaccines-blood-biologics/science-research-biologics
37. U.S. Food and Drug Administration. "Frequently Asked Questions About Drug Shortages" (manufacturing-quality problems as primary cause). https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
38. iShares. "IBB — iShares Biotechnology ETF" (fund mandate). https://www.ishares.com/us/products/239699/IBB